Ther4 is an Apo A-I fusion protein providing the main protein associated with HDL
Apo A-I typically has short half-life in the lipid-free state, whereas Ther4 has a longer half-life
Even with significant lowering of LDL cholesterol, there is residual risk for coronary heart disease thought to be due to dysfunctional HDL
Indication is to improve reverse cholesterol transport with potential to stabilize and/or reduce coronary plaques
TR-43
PON1 Fc molecule providing the antioxidant enzyme paraoxonase 1
This is a first-in-class molecule providing a long half-life to this important enzyme
The enzyme is deficient in many diseases including fibrosis and inflammation
There is also potential of this enzyme to provide protection from harmful chemicals such as pesticides and chemical nerve agents
There are promising data regarding prevention of diabetes in a rodent model of type 1 diabetes and treatment of insulin resistance in a different rodent model using recombinant PON 1
Paraoxonase Fusion Protein Platform
Bispecific molecules combined with the antioxidant enzyme paraoxonase 1
This is a first-in-class platform providing combination therapies for a multitude of diseases including heart disease and inflammatory conditions
US patent issued 12/31/24 covering Theripion bifunctional PON1 molecules
